Since the expression of these pro‐apoptotic proteins can be hindered by histone deacetylation [11, 12, 13], the objective of this study was to assess the efficacy of belinostat, a clinically used HDAC inhibitor, in increasing their expression levels and inducing apoptotic cell death in ovarian cancers. Here, HDAC9 is linked to ovarian cancer.